AREC - Arecor Therapeutics reveals deal with global medical products company
(NewsDirect)
Arecor Therapeutics PLC (AIM:AREC) ChiefBusiness Officer Manjit Rahelu speaks to Thomas Warner from Proactiveafter the biopharmaceutical group announced a significant developmentfrom its Specialty Hospital division.
A new collaboration with an unspecified "global medicalproducts company" will focus on reformulating a blockbusteroncology drug into a ready-to-use liquid form, enhancing itsefficiency and ease of use for patients.
This marks a significant shift from its powdered form, which wascomplex and time-consuming to prepare. The reconstituted drug is notonly more convenient but also aims to reduce waiting times forpatients, thereby improving overall healthcare delivery. Dr. Raheluhighlighted the collaborative effort involving a global partner withexpertise in R&D, manufacturing, commercialisation, and regulatoryaffairs.
This partnership aims toleverage both entities' strengths, combining Arecor'sinnovative in-house development with the partner's globalcapabilities. Arecor's technology has been instrumental in thisadvancement, underscoring their capability to apply their technologyacross various therapeutic areas beyond diabetes.
Thisdevelopment is the second major outcome from Arecor's in-housepipeline and Rahelu says it demonstrates Arecor's ability toindependently identify and develop promising candidates, translatingR&D efforts into value-driving collaborations.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.